Clinical significance of elevated serum chromogranin A levels

Clinical significance of elevated serum chromogranin A levels

Background: Chromogranin A (CgA) has been shown to be a useful marker in the diagnosis of neuroendocrine (NE) tumours. The clinical significance of CgA has been studied mostly in patients with known NE tumours. The diagnosis was evaluated in 153 consecutive patients in whom CgA was measured in a giv...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology Vol. 39; no. 10; pp. 969 - 973
Main Authors: Syversen, U., Ramstad, H., Gamme, K., Qvigstad, G., Falkmer, S., Waldum, H. L.
Format: Journal Article
Language:English
Published: Copenhagen Informa UK Ltd 01-10-2004
Oslo Taylor & Francis
Stockholm Scandinavian University Press
Subjects:
Adenocarcinoma
Adenocarcinoma - blood
Adenocarcinoma - diagnosis
Adolescent
Adult
Aged
Aged, 80 and over
atrophic gastritis
Biological and medical sciences
Biomarkers, Tumor - blood
Biopsy, Needle
Child
Chromogranin A
Chromogranins - blood
Chromogranins - metabolism
Cohort Studies
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Neoplasms - blood
Gastrointestinal Neoplasms - diagnosis
Humans
Immunohistochemistry
Male
Medical sciences
Middle Aged
Neuroendocrine Tumors - blood
Neuroendocrine Tumors - diagnosis
neuroendocrine tumour
Other diseases. Semiology
Probability
Prognosis
proton pump inhibitor
Radioimmunoassay
Sensitivity and Specificity
Severity of Illness Index
Statistics, Nonparametric
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
tumour marker
Adenocarcinoma
neuroendocrine tumour
Atrophic gastritis
Malignant tumor
Marker
Proton pump inhibitor
tumour marker
Chromogranin
Gastroenterology
Digestive diseases
Serum
chromogranin A
Gastric disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Chromogranin A (CgA) has been shown to be a useful marker in the diagnosis of neuroendocrine (NE) tumours. The clinical significance of CgA has been studied mostly in patients with known NE tumours. The diagnosis was evaluated in 153 consecutive patients in whom CgA was measured in a given time interval. Methods: CgA in serum was measured by radioimmunoassay. Immunohistochemistry with an antibody against CgA was performed in tumours from patients with adenocarcinoma and elevated CgA levels using a conventional method and the more sensitive tyramide signal amplification (TSA) technique. Results: Elevated serum CgA levels were found in 44 patients; 19 had NE tumours and 6 had tumours classified as adenocarcinomas. With the TSA technique, a high proportion of CgA-positive cells were disclosed in five of the adenocarcinoma patients. Patients with atrophic gastritis (no. 2) and patients treated with inhibitors of gastric acid secretion (no. 6) also had elevated levels of CgA. A modest increase in CgA levels was observed in 2 patients with renal impairment, and in 9 patients without any obvious cause. Conclusion: The current study confirms that serum CgA is a sensitive marker for the detection of NE neoplasia. Elevated levels found in patients with adenocarcinoma may indicate NE differentiation in the tumour. CgA is a useful tool in the monitoring of enterochromaffin-like (ECL) hyperplasia secondary to treatment with acid secretion inhibitors or atrophic gastritis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0036-5521
1502-7708
DOI:10.1080/00365520410003362